Nuformix plc (LON:NFX – Get Free Report)’s stock price was down 16.1% during trading on Wednesday . The company traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). Approximately 67,795,883 shares changed hands during trading, an increase of 635% from the average daily volume of 9,222,688 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Trading Down 17.7 %
The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12. The firm has a market capitalization of £417,848.10, a P/E ratio of -1.63 and a beta of 1.22. The firm has a 50 day moving average price of GBX 0.06 and a two-hundred day moving average price of GBX 0.14.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- Technology Stocks Explained: Here’s What to Know About Tech
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- How to Invest in the Best Canadian Stocks
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- What is Forex and How Does it Work?
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
